skip to main content

Title: PertInInt: An Integrative, Analytical Approach to Rapidly Uncover Cancer Driver Genes with Perturbed Interactions and Functionalities
A major challenge in cancer genomics is to identify genes with functional roles in cancer and uncover their mechanisms of action. We introduce an integrative framework that identifies cancer-relevant genes by pinpointing those whose interaction or other functional sites are enriched in somatic mutations across tumors. We derive analytical calculations that enable us to avoid time-prohibitive permutation-based significance tests, making it computationally feasible to simultaneously consider multiple measures of protein site functionality. Our accompanying software, PertInInt, combines knowledge about sites participating in interactions with DNA, RNA, peptides, ions, or small molecules with domain, evolutionary conservation, and gene-level mutation data. When applied to 10,037 tumor samples, PertInInt uncovers both known and newly predicted cancer genes, while additionally revealing what types of interactions or other functionalities are disrupted. PertInInt’s analysis demonstrates that somatic mutations are frequently enriched in interaction sites and domains and implicates interaction perturbation as a pervasive cancer-driving event.
Authors:
; ;
Award ID(s):
2006125
Publication Date:
NSF-PAR ID:
10220034
Journal Name:
Cell systems
Volume:
11
Page Range or eLocation-ID:
1 - 12
ISSN:
2405-4712
Sponsoring Org:
National Science Foundation
More Like this
  1. Data-driven discovery of cancer driver genes, including tumor suppressor genes (TSGs) and oncogenes (OGs), is imperative for cancer prevention, diagnosis, and treatment. Although epigenetic alterations are important for tumor initiation and progression, most known driver genes were identified based on genetic alterations alone. Here, we developed an algorithm, DORGE (Discovery of Oncogenes and tumor suppressoR genes using Genetic and Epigenetic features), to identify TSGs and OGs by integrating comprehensive genetic and epigenetic data. DORGE identified histone modifications as strong predictors for TSGs, and it found missense mutations, super enhancers, and methylation differences as strong predictors for OGs. We extensively validated DORGE-predicted cancer driver genes using independent functional genomics data. We also found that DORGE-predicted dual-functional genes (both TSGs and OGs) are enriched at hubs in protein-protein interaction and drug-gene networks. Overall, our study has deepened the understanding of epigenetic mechanisms in tumorigenesis and revealed previously undetected cancer driver genes.
  2. Abstract

    AGAMOUS-Like 18 (AGL18) is a MADS domain transcription factor (TF) that is structurally related to AGL15. Here we show that, like AGL15, AGL18 can promote somatic embryogenesis (SE) when ectopically expressed in Arabidopsis (Arabidopsis thaliana). Based on loss-of-function mutants, AGL15 and AGL18 have redundant functions in developmental processes such as SE. To understand the nature of this redundancy, we undertook a number of studies to look at the interaction between these factors. We studied the genome-wide direct targets of AGL18 to characterize its roles at the molecular level using chromatin immunoprecipitation (ChIP)-SEQ combined with RNA-SEQ. The results demonstrated that AGL18 binds to thousands of sites in the genome. Comparison of ChIP-SEQ data for AGL15 and AGL18 revealed substantial numbers of genes bound by both AGL15 and AGL18, but there were also differences. Gene ontology analysis revealed that target genes were enriched for seed, embryo, and reproductive development as well as hormone and stress responses. The results also demonstrated that AGL15 and AGL18 interact in a complex regulatory loop, where AGL15 inhibited transcript accumulation of AGL18, while AGL18 increased AGL15 transcript accumulation. Co-immunoprecipitation revealed an interaction between AGL18 and AGL15 in somatic embryo tissue. The binding and expression analyses revealedmore »a complex crosstalk and interactions among embryo TFs and their target genes. In addition, our study also revealed that phosphorylation of AGL18 and AGL15 was crucial for the promotion of SE.

    « less
  3. Directional association measured by functional dependency can answer important questions on relationships between variables, for example, in discovery of molecular interactions in biological systems. However, when one has no prior information about the functional form of a directional association, there is not a widely established statistical procedure to detect such an association. To address this issue, here we introduce an exact functional test for directional association by examining the strength of functional dependency. It is effective in promoting functional patterns by reducing statistical power on dependent non-functional patterns. We designed an algorithm to carry out the test using a fast branch-and-bound strategy, which achieved a substantial speedup over brute-force enumeration. On data from an epidemiological study of liver cancer, the test identified the hepatitis status of a subject as the most influential risk factor among others for the cancer phenotype. On human lung cancer transcriptome data, the test selected 1068 transcription start sites of putative noncoding RNAs directionally associated with the presence or absence of lung cancer, stronger than 95 percent transcription start sites of 694 curated cancer genes. These predictions include non-monotonic interaction patterns, to which other routine tests were insensitive. Complementing symmetric (non-directional) association methods such as Fisher’smore »exact test, the exact functional test is a unique exact statistical test for evaluating evidence for causal relationships.« less
  4. Cancer is a complex disease associated with abnormal DNA mutations. Not all tumors are cancerous and not all cancers are the same. Correct cancer type diagnosis can indicate the most effective drug therapy and increase survival rate. At the molecular level, it has been shown that cancer type classification can be carried out from the analysis of somatic point mutation. However, the high dimensionality and sparsity of genomic mutation data, coupled with its small sample size has been a hindrance in accurate classification of cancer. We address these problems by introducing a novel classification method called mClass that accounts for the sparsity of the data. mClass is a feature selection method that ranks genes based on their similarity across samples and employs their normalized mutual information to determine the set of genes that provide optimal classification accuracy. Experimental results on TCGA datasets show that mClass significantly improves testing accuracy compared to DeepGene, which is the state-of-the-art in cancer-type classification based on somatic mutation data. In addition, when compared with other cancer gene prediction tools, the set of genes selected by mClass contains the highest number of genes in top 100 genes listed in the Cancer Gene Census. mClass is availablemore »at https://github.com/mdahasan/mClass.« less
  5. Abstract BACKGROUND

    Despite widespread interest in next-generation sequencing (NGS), the adoption of personalized clinical genomics and mutation profiling of cancer specimens is lagging, in part because of technical limitations. Tumors are genetically heterogeneous and often contain normal/stromal cells, features that lead to low-abundance somatic mutations that generate ambiguous results or reside below NGS detection limits, thus hindering the clinical sensitivity/specificity standards of mutation calling. We applied COLD-PCR (coamplification at lower denaturation temperature PCR), a PCR methodology that selectively enriches variants, to improve the detection of unknown mutations before NGS-based amplicon resequencing.

    METHODS

    We used both COLD-PCR and conventional PCR (for comparison) to amplify serially diluted mutation-containing cell-line DNA diluted into wild-type DNA, as well as DNA from lung adenocarcinoma and colorectal cancer samples. After amplification of TP53 (tumor protein p53), KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), IDH1 [isocitrate dehydrogenase 1 (NADP+), soluble], and EGFR (epidermal growth factor receptor) gene regions, PCR products were pooled for library preparation, bar-coded, and sequenced on the Illumina HiSeq 2000.

    RESULTS

    In agreement with recent findings, sequencing errors by conventional targeted-amplicon approaches dictated a mutation-detection limit of approximately 1%–2%. Conversely, COLD-PCR amplicons enriched mutations above the error-related noise, enabling reliable identification of mutation abundances of approximatelymore »0.04%. Sequencing depth was not a large factor in the identification of COLD-PCR–enriched mutations. For the clinical samples, several missense mutations were not called with conventional amplicons, yet they were clearly detectable with COLD-PCR amplicons. Tumor heterogeneity for the TP53 gene was apparent.

    CONCLUSIONS

    As cancer care shifts toward personalized intervention based on each patient's unique genetic abnormalities and tumor genome, we anticipate that COLD-PCR combined with NGS will elucidate the role of mutations in tumor progression, enabling NGS-based analysis of diverse clinical specimens within clinical practice.

    « less